DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The Effectiveness of Two Osteoporosis Drugs on Prosthetic Bone Mineral Density (BMD) Loss After Total Hip Arthroplasty(THA)

Information source: Yokohama City University Medical Center
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Bone Density; Arthroplasty, Replacement, Hip

Intervention: alendronate, alfacalcidol (Drug)

Phase: N/A

Status: Active, not recruiting

Sponsored by: Yokohama City University Medical Center


The purpose of this study is to evaluate whether alendronate and alfacalcidol are effective on prosthetic or lumbar spine BMD after total hip arthroplasty.

Clinical Details

Official title: A Comparison of Alendronate vs. Alfacalcidol Medication for the Preservation of Bone Mineral Density Around the Femoral Implant and in the Lumbar Spine After a Total Hip Arthroplasty

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: DEXA QDR 2000, Hologic Co.


Minimum age: 44 Years. Maximum age: 82 Years. Gender(s): Both.


Inclusion Criteria:

- osteoarthritis of the hip

- patients after total hip arthroplasty

Exclusion Criteria:

- diseases related to bone metabolism

- patients taking drugs which affect bone metabolism

Locations and Contacts

Department of orthopaedic surgery, Yokohama City University, Yokohama, Kanagawa, Japan
Additional Information

Starting date: January 2006
Last updated: December 2, 2009

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017